What did they Say About Biomatec-US

admin — Sun, 06 Jun 2010 19:29:47 +0000

Dr Driss OUAOUICHA, President, Al Akhawayn University in Ifrane
I was very pleased and impressed with the seriousness of your association and its members. I hereby reiterate the invitation to host one of your meetings at AUI, where more of your fellow researchers in Morocco could participate.

Ambassador Aziz Mekouar

It was a real pleasure to attend the annual meeting of the MASLS. Please convey my congratulations and my best regards to all of your members. Morocco can be proud of you all.

Wiegmann, Daniel D, Program Director in the Division of Integrative Organismal Systems, NSF.

It was my pleasure to talk with members of your organization Biomatec. I was very impressed with the dedication of the attendees and I hope to see some grant proposals as a result of our interactions.

Gary L. Garrison, Council for International Exchange of Scholars

I’m grateful to Biomatec for thinking of Fulbright as a means to encourage greater cooperation between Morocco and the US and for inviting me to the Biomatec-US annual meeting. We’ll be pleased to provide any other information to members of the Society on Fulbright opportunities for Moroccan or American scholars.

Bio of Abdelkrim Smine, Ph.D.

admin — Thu, 03 Sep 2009 15:23:41 +0000

Bio of Abdelkrim Smine, Ph.D.

v BS Biologie General: Univ. Mohamed V – Casablanca – Morocco

v 1991: DEA Marine Biotechnology. Univ. Marseille – France

v 1995: Ph.D. Marine Biotechnology. Univ. Marseille & Collège de France– France

Purification and characterization of marine bio-active peptides. Identification of biological activities on skin cells regeneration.

v 1995-1997- Post doc in Case Western Reserve University Cleveland-OH (USA). The role of the matrix metalloproteinases and their inhibitors on Age Related Macular Denegation.

v 1997-2001 – Research associate; Cleveland Clinic Foundation. Molecular pathologies of Alzheimer’s disease and signaling of TGF beta.

v Earned a National Research Award Fellowship from NIH (1998-2001)

v 2001- present: United States Pharmacopeia (senior scientist to Manager). Managed a drug quality and information program; in Africa, Latin America and South East Asia. Earned over 10 awards for outstanding performance, expanded the program from 6 to over 34 countries and the budget from 3 to $ 28 Million. My areas of expertise; Drug regulations, Drug quality assurance, manufacturing, Good Lab Practices, training and certification, clinical studies, Quality systems and business strategies for private labs and drug manufacturers

v 2007-2008 : Head of drug Regulations in UAE.

In charge of drug regulations, Quality Control, Pharmacovigilance, drug information center and post-marketing surveillance

v Present: Senior consultant and advisor with the United States Pharmacopeia.

Founder and president of Pharmaceutical Quality Solution International, LLC, (MD, USA) specialized in consulting and technical support of drug manufacturers, regulators and QC labs.
Founder and President of Laboratory Technologies SARL (Casa – Morocco); Specialized in lab technologies, equipment, training and consulting.

v Private Consultant with various organizations and government institutions (USP, USAID, WHO, UNICEF, DUBIOTECH, private medicines Manufacturers, Saudi Lab Projects…).

v AWARDS

- National Institute of Health Research Award Fellowship, 1998-2001

- Daniel Jouvance Marine Biotechnology Grant (France), 1991- 1994

- National merit scholarship from the government of Morocco, 1986-1990

v Recent Publications:

A. Smine, J. Carpenter, C. Walker and O. Fontaine (2008) Guidelines for Pharmaceutical manufacturers for Zinc. WHO – Geneva. ISBN 978 92 4 259494 2
Deborah Armbruster et.al, A. Smine (2007). The use of chlorhexidine to reduce maternal and neonatal mortality and morbidity in low-resource settings. International Journal of Gynecology and Obstetrics Volume 97, Issue 2, 89-94.
Lon Chanthap, S. Phanouvong, A. Smine (2006) Counterfeit and Substandard Anti-Malarial Drugs in Cambodia. TRSTMH.
N. Morse, S. Brabdy. P. White, M. Sharaf, S. Wahab, B. Chaw and A. Smine (2006) Validation of the use of TLC to test the identity of antiretroviral drugs. Journal of Chromatography.
Assessment of drug quality assurance of five countries in South East Asia (2002). The world Health Organization resource publication.

Abdelkrim Smine, Ph.D.

Tel: 301-850-4902 or + 212-0661-387817. E-mail: karimdqi@yahoo.com

Dr. Nadia Amrani

admin — Mon, 18 May 2009 18:16:47 +0000

Dr. Nadia Amrani is a native of Marrakech (Morocco), where she attended The University of Sciences Cadi Ayad and obtained her Bachelor Degree with distinction in Biology in 1990. She moved then to Toulouse (France) to pursue her undergraduate studies at the Ecole Nationale Supérieure Agronomique de Toulouse where she obtained her first Master Degree in Plant Biotechnology in 1991. In 1992, Dr. Amrani obtained her second Master Degree (DEA) from the same institution where she published two of her first scientific research papers. Her main project was to develop assays to regenerate and produce haploid plants in crosses between tetraploid and hexaploid wheat and maize. Dr. Amrani started her doctorate work in the Department of Molecular Genetics at the Centre National de la Recherche Scientifique (CNRS) at Gif-Sur-Yvette (France), in affiliation with the University of Pierre et Marie-Curie, Paris. During her graduate studies in France, she applied for and won different fellowships from A.R.C. (Association pour la Recherche contre le Cancer, 1996-1997), from the CNRS (1994-1997), and from the government of Morocco (1991-1997). In 1997 she obtained her PhD with the highest award and published three scientific papers. Prior to moving to the United States, she obtained a fellowship from Human Frontier Science Program (1998-2000) and started her postdoctoral training in the Department of Molecular Genetics and Microbiology at The University of Massachusetts (Worcester, US) where she holds currently a position of Research Assistant Professor. Dr. Amrani’s most recent work was published in the prestigious scientific journal Nature, where she describes a new model of the closed loop mRNP structure which forms during translation initiation in eukaryotes. Dr. Amrani won Biomatec’s 2008 Award as a recognition for her excellent scientific contribution and for her active participation in the organization of the 2008 Biomatec Annual Meeting. Dr. Amrani is married to Dr. Mustapha Abdelouahed, they both live with their three daughters, Sara, Weaam and Rania, in Worcester, Massachusetts (US). She became a naturalized United States citizen in 2008. The most recent of Dr. Amrani’s publications are:

• Amrani, N., Ghosh, S., Mangus, D.A., and Jacobson, A. Translation factors promote formation of two states of the closed loop mRNP. Nature, 453: 1276-1280, 2008.
• He, F., Amrani, N., Johansson, M.J.O., and Jacobson, A. Qualitative and quantitative assessment of the activity of the yeast NMD pathway. In: Methods in Enzymology Vol. 449. RNA Turnover (Editors: L. Maquat and M. Kiledjian), Elsevier, San Diego, pp. 127-148, 2008.
• Wu, C., Amrani, N., Jacobson, A. and Sachs, M. S. The use of fungal in vitro systems for studying translational regulation. In: Methods in Enzymology Vol. 429. Translation Initiation: Extract Systems and Molecular Genetics (Editor: J. Lorsch), Elsevier, San Diego, pp. 203-225, 2007.
• Amrani, N. and Jacobson, A. All termination events are not equal: premature termination in yeast is aberrant and triggers NMD. In: Nonsense-mediated mRNA decay (Editor: L.E. Maquat), Landes Bioscience, Texas, pp. 15-25, 2006.
• Amrani, N., Sachs, M. S. and Jacobson, A. Early nonsense: mRNA decay solves a translational problem. Nat Rev Mol Cell Biol, 7: 415-425, 2006.
• Amrani, N., Dong, s., He, F., Ganesan, R., Ghosh, S., Kervestin, S., Li, C., Mangus, D. A., Spatrick, P. and Jacobson, A. Aberrant termination triggers nonsense-mediated mRNA decay. Biochem Soc Trans, 34: 39-42, 2006.
• Amrani, N., Ganesan, R., Kervestin, S., Mangus, D. A., Ghosh, S. and Jacobson, A. A faux 3′-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature, 432: 112-118, 2004.
• Kervestin, S., and Amrani, N. Translational regulation of gene expression. Genome Biol., 5 (12): 359-1.3, 2004.

Constitution

admin — Fri, 20 Mar 2009 20:15:23 +0000

[Download the PDF 52 KB]

Articles of Incorporation of The Moroccan-American Society for Life Sciences

We, the undersigned, being of legal age, and for the purpose of forming a corporation under and pursuant to the provisions of the District of Columbia Nonprofit Corporation Act, and laws amendatory thereof and supplementary thereto, do hereby form a body corporate and adopt the following Articles of Incorporation:

ARTICLE 1
The name of this corporation shall be Moroccan-American Society for Life Sciences
and the moniker "BIOMATEC" will be used to identify it.

ARTICLE 2
The purpose for which BIOMATEC is formed is to gather life scientists, particularly Moroccans with graduate school training, to work toward the following goals:

o To promote scientific advances,
o To serve as a bridge between scientific communities and organizations,
especially between those in the United States of America and The Kingdom of
Morocco,
o To organize scientific events and publications,
o To provide support to scientists, particularly those from Morocco,
o To collaborate with other organizations sharing these goals.

ARTICLE 3
No part of the net earnings of BIOMATEC shall be used to the benefit of, or be distributable to its members, officers, or other private persons, except that the corporation shall be authorized and empowered to pay Reasonable compensation for services rendered and to make payments and distributions in furtherance of its purposes.

BIOMATEC is organized exclusively for charitable, educational, and scientific purposes, including, for such purposes, the making of distributions to organizations that qualify as exempt organizations under section 501 (c) (3) of the Internal Revenue Code of 1954 (or corresponding section of any future Federal Tax Code). BIOMATEC is a non-governmental, a non-profit organization, with no political or religious affiliation. Therefore BIOMATEC shall not participate in, help finance, or lend its name to any activities aimed at furthering the political aspirations of any candidate for public office or any political party, nor will it engage in advocacy of any positions other than those which are within the realm of serving the advancement of the life sciences in general.

Notwithstanding any other provision of these articles, BIOMATEC shall not carry on any activities not permitted to be carried on (a) by a corporation exempt from Federal Income Tax under section 501(c)(3) of the Internal Revenue Code of 1954 (or the corresponding provision of any future United States Internal Revenue Law) or (b) by a corporation, contributions to which are deductible under section 170(c)(2) of the Internal Revenue Code of 1954 (or the corresponding provision of any future United States Internal Revenue Law).

ARTICLE 4
BIOMATEC shall have all the powers granted or available to a non-profit corporation under the laws of the state of "name of the state".

ARTICLE 5
BIOMATEC shall not issue, nor shall it cause to be issued, any shares of capital stock.

ARTICLE 6
The registered office of BIOMATEC shall be located in New Jersey, U.S.A.

ARTICLE 7
The period of duration of BIOMATEC shall be perpetual.

ARTICLE 8
Upon the dissolution of BIOMATEC, the Board of Directors shall, after paying or making provision for the payment of all liabilities of the corporation, dispose of all of the assets of the corporation exclusively for the purposes of the corporation in such manner, or to such organization or organizations organized and operated exclusively for charitable, educational, or scientific purposes as shall at the time qualify as exempt organization or organizations under section 501(c)(3) of the Internal Revenue Code of 1954 (or the corresponding provision of any future United States Internal Revenue Law), as the Board of Directors shall determine. Any such assets not so disposed of shall be disposed of by the Court having jurisdiction over it of the county in which the principal office of the corporation is then located, exclusively for such purposes or to such organization or organizations, as said Court shall determine, which are organized and operated exclusively for such purposes.

ARTICLE 9
BIOMATEC shall be governed by these articles and the "by-laws". Amendments to either can be proposed by the board of directors and approved by two-thirds (2/3rds) of the voting members in attendance at an Annual meeting. If fifteen percent (15%) of the voting members propose a change to the articles of incorporation or the by-laws, the board must present the same to the annual meeting for a vote, which will require approval by two-thirds (2/3rds) of the voting members in attendance to take effect. Whether offered by the board or the voting members, any proposed amendments must be sent to all members at a reasonable delay before the voting date.

ARTICLE 10
Though it is anticipated that most members of BIOMATEC will be Moroccan Biologists living in the United States, individuals not living in the USA and friends of Morocco are very welcome to apply. Two categories of membership are recognized; voting and supporting:

- Voting members are life scientists who have paid their annual membership fees
- Supporting members are all others interested in the vision and mission of BIOMATEC.

Only Voting members have right of vote. The Board of Directors reserves the rights to deny or discontinue any memberships to individual who do not respect these Articles or the By-Laws of BIOMATEC, or whose activities are opposed to BIOMATEC’s goals. Membership in BIOMATEC shall be granted by, and be subject to, any conditions set forth by its Board of Directors. Those granted membership shall not acquire any power to act for or on behalf of BIOMATEC.

ARTICLE 11
The conduct of the affairs of BIOMATEC shall be vested in a Board of Directors consisting of at least five (5) and not more than fifteen (15) members, as provided for from time to time in the By-Laws. The By-Laws shall provide the exact term and tasks of the board of directors. Board members are elected during a meeting, known as the general assembly.

A completion of a voting membership in BIOMATEC for at least one year is required to be eligible for a seat in the Board of Directors. Removal of a member of the Board of Directors can occur by a vote of two-thirds of all sitting members of the Board, or after a duly called vote at which at least two thirds (2/3rds) of the voting members of BIOMATEC vote for removal.

Executive decisions of the Board of Directors require a majority vote of the quorum present in the period of the vote. The quorum shall include the president or one of the vice-presidents and shall have at least two-thirds (2/3rds) of board members. In case of a tie, vote of the President, or in the president’s absence, vote of the Vice-President (s), will determine the outcome.

ARTICLE 12
The names and post office addresses of the incorporators of BIOMATEC are as follows in alphabetical order:

My Abdelmajid Kassem, Ph.D. Department of Biological Sciences
Kean University, Union, NJ 07083

BY-LAWS of The Moroccan-American Society for Life Sciences

ARTICLE I : NAME AND LOCATION
Section 1: The name of this non-profit, non-governmental corporation shall be " The Moroccan-American Society for Life Sciences" and the moniker "BIOMATEC" will be used to identify it.

Section 2: The registered office of BIOMATEC shall be located in New Jersey., U.S.A.

Section 3: Other Offices for the transaction of business shall be located at such places
as the Board of Directors may from time to time determine.

ARTICLE II : VISION, MISSION AND OBJECTIVES
Section 1: Science and Technology present a vital role in the sustained development process of a given country. Biotechnology is particularly of well-acknowledged importance. BIOMATEC vision is to serve as an example in technology and knowledge transfer to developing countries.

The Kingdom of Morocco will be the model. BIOMATEC aims to respond to diverse needs of Moroccan institutions in sciences, by offering information support, technical expertise transfer, educational assistance, and other services that would improve the scientific standards and the level of biotechnological industries and businesses. Section 2: BIOMATEC’s mission is to gather scientists, particularly Moroccans with graduate school training, to work towards the following goals:

o To promote scientific advances,
o To serve as a bridge between scientific communities and organizations, especially between those in the United States of America and The Kingdom of
Morocco,
o To organize scientific events and publications,
o To provide support to scientists, particularly those from Morocco,
o To collaborate with other organizations sharing these goals.

ARTICLE III : BOARD OF DIRECTORS AND OFFICERS
Section 1: The business and property of BIOMATEC shall be managed by a Board of
Directors composed of five members elected during the general assembly’s duly
called vote.

Section 2: A committee of volunteers or nominated members shall organize the general assembly, which shall take a place a month to a day before the date of expiration of the outgoing board’s term.

Section 3: To qualify as a candidate for a seat in the Board of Directors a completion
of a voting membership in BIOMATEC for at least one year is required.

Section 4: Except when a vacancy occurs in the Board of Directors because of expansion of the number of Directors, or to fill a vacancy caused by the death, resignation or removal of a Director, each member of the Board of Directors shall serve for a two year term which shall start the day after the expiration date of the outgoing Board’s term.

Section 5: Removal of one or all members of the Board of Directors is effective after a
duly called vote by at least two-thirds (2/3rds) of voting members.

Section 6: Executive decisions of the Board of Directors require a majority vote of the quorum present in the period of the vote. The quorum shall include the president or one of the vice-presidents and shall contain at least two-thirds (2/3rds) of Board members. In case of a tie, vote of the President, or in the president’s absence, vote of the Vice-President (s), will determine the outcome.

Section 7: To fill vacancies in the Board, the quorum of the Board of Directors shall elect, by a majority vote, eligible members whose term will end the same date as the elected Board’s term.

Section 8: In the beginning of its term, the Board of Directors shall elect for up to the end of its term,

Section 9: The duties of the officers shall be those generally

Section 10: For a particular mission, the Board of Directors

Section 11: Special meetings of the Board may be called by

Section 12: The Board of Directors must send BIOMATEC’s annual

ARTICLE IV : MEMBERSHIP IN BIOMATEC
Section 1: The Board of Directors shall set forth standards whereby individuals who are interested in supporting the aims

Section 2: A membership in BIOMATEC is an engagement to respect

Section 3: Annual membership fees are due by all members

Section 4: Both Directors and members are granted the right

Section 5: No member can act for or on behalf of BIOMATEC,

Section 6: The Board of Directors reserves the right to deny

ARTICLE V: GENERAL ASSEMBLY, MEETINGS AND VOTES
Section 1: For the purposes of notifying voting members of the general assembly, annual meetings, proposed amendments,

Section 2: The general assembly or the meetings can be attended

Section 3: The general assembly, meetings, votes, activities

Section 4: Only voting members have right of vote.

Section 5: The general assembly shall be presided over by

Section 6: If any voting member can not attend a meeting,

by a majority vote, each of the following officers: a President, a Vice- President, a Secretary, an officer and a Treasurer.

held to be the normal duties of a corporation officer of that office.

may appoint committees, which shall be under the close supervision of a designated member of the Board. The structure and function of each permanent committee shall be then detailed in the By-Laws.

the president or by two fifths of the Board’s members.

financial and activity reports to all members, by the end of each year.

of BIOMATEC, as set forth from time to time by the Board, can become members of "The Moroccan American Society for Life Sciences". The Board shall solicit the views of members on topics that are relevant to BIOMATEC and seek to utilize their talents to further the aims of its activities.

the ruling texts and to help accomplishing the mission, vision and objectives of the Corporation.

and no membership is valid before fee payment. Its amount is set to $ 15 for students, $ 50 for faculty, and $35 for all others. Exemption from annual membership fees may be considered upon a request to the Board of Directors.

to inspect the organization’s properties and finances. Members who would like to, should address an official request to the Board of Directors.

except the Board of Directors by an official statement.

or discontinue any membership to individuals who do not respect the articles of incorporation or the By-Laws of BIOMATEC, or whose activities are opposed to BIOMATEC’s goals. Should this happen, all members must be informed and the reason (s) clearly explained.

or any activity, The Board of Directors can use postal mail as well as electronic mail for communication.

in person or organized through Internet.

or any event shall be duly called and the reasons of the event communicated to all members, by the Board of Directors, at least eight weeks, if attending in person is necessary, otherwise at least two weeks prior to the date of the event.

BIOMATEC’s president, or in the president’s absence by the vice-president, or if the board decides otherwise, by any other member designated or elected by the board of directors.

that member might vote, at the Board’s discretion, by means of electronic communication or could appoint, by written statement, another voting member, to represent and carry on that meeting’s vote on his/her behalf.

BIOMATEC-US 7th Annual Meeting 2008

admin — Fri, 20 Mar 2009 18:07:15 +0000

Presentation
Video Projection for the 2008 dinner event with Dr Zerhouni, NIH Director as Guest of Honor (see program for details)

Invited Guest Speaker: George Y. Wu, M.D., Ph.D., Professor, University of Connecticut Health Center.

Invited Guest Speaker: Pam Weathers, Ph.D., Professor, Worcester Polytechnic Institute.

Invited Guest Speaker: Nadia Amrani, Ph.D., Research Assistant Professor, University of Massachusetts.

Meeting Description

This meeting will bring together the Moroccan Scientific Community of North-America. We are expecting 80-100 participants mainly from the States and Canada. The primary goal of the meeting is to create a framework to strengthen the network of Moroccan Scientists by increasing contacts and collaborations. In addition, a well tailored scientific program will expose the latest advancements in the fields of biomedicine, plant diseases, and novel technologies. This meeting will focus on Infectious and Cancer Diseases, as well as a session on pharmaceutical industry. A debate will be animated on the “Voluntary Work”. Finaly, a new Board of Directors will be elected for the next term (June-2008 to May-2010).

The meeting will take place in the Conference Room at the WPI-MBI, located at Gateway Park, 60 Prescott Street, Worcester, MA 01605.

Registration Fees: (donations higher than the fees indicated below are welcome)
	Meeting fee alone	Meeting fee + Biomatec Membership
Students	$ 20	$ 30
Faculty, Scientists	$ 50	$ 80
Postdocs, and others	$ 35	$ 60

Deadline for registration, abstract submission, and hotel reservation with negotiated rate:

May 2nd 2008

Meeting Organizers:
Mustapha Abdelouahed Ph.D., Chair, WesaGen Inc., MA.
Nadia Amrani Ph.D., Co-Chair, University of Massachusetts, MA.
Mounir Izalallen Ph.D., Co-Chair, University of Massachusetts, MA.
Mohamed Arredouani Ph.D., Co-Chair, Harvard Medical School, MA
Kamal Elbissati Ph.D., Albert Einstein College of Medicine, NY
Abdelmajid Kassem Ph.D., Fayetteville State University, NC
Hassan Badrane Ph.D., University of Pittsburgh, PA

Meeting Sponsorship:
We are gratefull to the following sponsors:
Worcester Polytechnic Institute (WPI)
Massachusetts Biomedical Initiatives (MBI)
WesaGen Inc
BIOMATEC-US also appreciate the help of Crowne Plaza Worcester for providing a quality accomodation for participants. Crowne Plaza Worcester will be the exclusive Hotel accomodation for participants.

Program

Download FINAL PROGRAM (PDF)

Preliminary Program Format

FRIDAY, May 23rd:
5:00-7:30 pm Registration, Reception (Conference Room) and touring the Massachusetts Biomedical Initiatives facilities, which host dozens start up biotech companies, lab facilities and Bioengineering labs

SATURDAY, May 24th:
08:00-09:00 am | Registration and Light Breakfast
09:00-09:15 am | Welcome and Introduction (Meeting Chair, Biomatec-US & BioACM Presidents)

9:15-11:00 am | Session I: Infectious Diseases
Chairperson: Dr. Hassan Badrane, University of Pittsburgh, PA

– Dr. P. Weathers, Professor, Worcester Polytechnic Institute
- Dr. K. El-Bissati, Albert Einstein College of Medicine
- Dr. G. Wu, Professor, University of Connecticut Health Center

11:00–11:30 am | Coffee Break

11:30-12:30 pm | Session II: Genetic & Cancer Diseases
Chairperson: Dr. Mustapha Kandouz, McGill University, QC

– Dr. Nadia Amrani, Assistant Professor, University of Massachussets
- Dr. Abderahman El Maarouf, Memorial Sloan-Kettering Cancer Center
- Dr. Taha Merghoub, Memorial Sloan-Kettering Cancer Center

12:30- 2:00 pm | Lunch Break

2:00- 3:00 pm | Session III: Pharmaceutical Sciences
Chairperson: Dr. Abdellah Nihran,

– Dr. Youssef Bennani, V.P. Drug Innovation, Vertex Pharmaceuticals, MA (to be confirmed)
- Dr. Mohammed Taimi, Principal Scientist, Synta Pharmaceuticals Corp., MA
- Dr. Hicham Alaoui, Director of Biology, Stryker Biotech, MA
- General Discussion, questions/answers

3:00- 3:30 pm | Coffee Break

3:30- 5:00 pm | Session IV: Maghreb Bridging
Chairperson: Dr Mohammed Bourdi, NIH, MD

2008 dinner event with Dr Zerhouni, NIH Director as Guest of Honor: More than 30 scientists in biomedical filed from Washington DC area, from the Maghreb gathered with Dr. Elias Zerhouni. The dinner was graciously hosted by the Moroccan Ambassador to the US, Mr. Aziz Mekouar. A symbolic Award was presented to Dr. Zerhouni, to acknowledge his efforts in promoting scientific research in the Maghreb region. A video of the event will be projected followed by a discussion about cooperation of scientists from the Maghreb

[View with PicLens]

.

5:00- 6:00 pm | BIOMATEC Business

– Annual Reports
- Election of a new Board of Directors

6:00- 10:00 pm | Dinner (location to be announced)

Participants

BIOMATEC-US / BioACM 7th Annual Meeting – Participants

The number of participants, who so far completed their registration, is: 33

This is a temporary list of these participants:

Name	Title	Institution	Country
Hassan Fahmi	Ass. Professor	University of Montreal	Canada
Mouna Lagraoui	Research Scientist	Prometic Biosciences	Canada
Mustapha Kandouz	Project director	McGill University	Canada
Dr. Khalid Sendide	Assistant Professor	Al-Akhawayn University, Ifrane	Morocco
Fouad Barada	Associate Professor	Al-Akhawayn University, Ifrane	Morocco
Abdelmajid Kassem	Associate Professor	Fayetteville State University	United States
Abderrahman El Maarouf	Senior Scientist	Sloan-Kettering Institute, NY	United States
Allal Boutajangout	Research Assistant Professor	NYU Medical Center	United States
Amina Soukrati	Research Fellow	Northeastern University	United States
Fatiha Bouricha	Inform. Sys. & Database Manager	Boston Living Center	United States
George Y. Wu	Professor and Chairman	University of Connecticut Medical School	United States
Hassan Badrane	Research Assistant Professor	University of Pittsburgh	United States
Hassan Brim	Postdoctoral	Howard University, Washington, DC	United States
Hicham Alaoui	Director of Biology	Stryker Biotech, MA	United States
Hicham Drissi	Associate Professor	University of Connecticut Health Center	United States
Kamal El Bissati	Instructor	Albert Einstein College of Medicine, NY	United States
Khadija Iken	Postdoctoral	Beth Israel Deaconess Hospital, Boston, MA	United States
Larbi Zouak	DMD	Zouaks Dental Health Associates LLC	United States
Lhoucine Seffiani	Medical Technologist II	Massachusetts General Hospital / Partners	United States
Melissa Caimano	Assistant Professor	University of Connecticut Medical School	United States
Mohamed Belkziz	Systems Engineer	Partners HealthCare System Inc.	United States
Mohamed Trebak	Assistant Professor	Albany Medical College	United States
Mohammed Bourdi	Staff Scientist	National Institutes of Health	United States
Mohammed Taimi	Principal Scientist	Synta Pharmaceuticals Corp., MA	United States
Mounir Izallalen	Postdoctoral	University of Massachusetts, Amherst	United States
Mustapha Abdelouahed	CEO	Wesagen Inc., MA	United States
Nadia Amrani	Research Assistant Professor	University of Massachusetts Medical Scho	United States
Pamela Weathers	Professor	Worcester Polytechnic Institute, MA	United States
Simo Arredouani	Instructor	Beth Israel Deaconess Medical Center	United States
Taha Merghoub	Assistant Lab member	MSKCC	United States
Tahar El-korchi	Professor & Head	WPI	United States
Youssef Bannani	Vice President	Drug Innovation, Vertex Pharmaceuticals, MA	United States
Zahra Mamdouh	Research Assistant Professor	Northwestern University	United States

Accommodation

Hotel Accommodation :

The Organizing Committee is pleased to offer to participants an accomodation at a negotiated rate. Crowne Plaza Worcester will be the hotel accomodating participants for the meeting. The Hotel is centrally located in downtown Worcester and is within walking distance (0.3 miles) from the conference room. Participants will have double or king rooms avaiable at $106 (+taxes) per night per room. Participants should call the hotel directly (phone: 1-508-791-1600) to reserve their room, you should mention “Biomatec Conference” to get the negotiated rate. This rate will be honored until May 2, 3:30 p.m. However, please be advised space is limited, and the hotel reserves the right to deny this rate if Hotel is overbooked. If you plan to share the room and looking for roomate, please mention that in your Online regitration. The organizers will also arrange free pick-up of participants from Airport, please let us know if you need such a service.

All About The Human Genome Project (HGP)

admin — Tue, 17 Mar 2009 22:14:53 +0000

All About The Human Genome Project (HGP)

The Human Genome Project (HGP) was one of the great feats of exploration in history – an inward voyage of discovery rather than an outward exploration of the planet or the cosmos; an international research effort to sequence and map all of the genes – together known as the genome – of members of our species, Homo sapiens. Completed in April 2003, the HGP gave us the ability to, for the first time, to read nature’s complete genetic blueprint for building a human being.

In this section, you will find access to a wealth of information on the history of the HGP, its progress, cast of characters and future.

	Educational Resources
	General Information
	Research
	Model Organisms

Educational Resources

A Guide to Your Genome
Comprehensive and easy to understand information about your genome.
Understanding the Human Genome Project
NHGRI’s Online Education Kit
An Overview of the Human Genome Project
A brief overview of the HGP.
50 Years of DNA: From Double Helix to Health
Information about the celebration of the completion of the HGP and the 50th anniversary of the discovery of the double helix structure of DNA.
News About the HGP
Links to news releases announcing key moments in the history of the HGP.
About the National Human Genome Research Institute
Fact sheet about NHGRI.

Top of page

General Information

Human Genome Project
A general fact sheet on the Human Genome Project from the National Institutes of Health.
The Human Genome Project Completion: Frequently Asked Questions
Background information about the HGP created for the media.
Human Genome Project Goals
Includes definitions of key terms.
What’s Next? Turning Genomics Vision Into Reality
Information about NHGRI projects made possible by the completion of the HGP.
The Future of Genomics
Testimony Before the United States House of Representatives on May 22, 2003.
International Human Genome Sequencing Consortium
A list of the sequencing centers that participated in the HGP.
About the National Human Genome Research Institute: A History and Timeline
Highlights key events in the history of the HGP.
Long-Range Planning: Shaping A Vision for the Future of Genomics
Basic information about the long-range planning since the HGP was completed.
- For a list of groups taking part in this planning, see Long-Range Planning Groups.
- For information on meetings and workshops involved in this planning, see Long-Range Planning: Reports and Publications
Budget and Financial Information
Frequently Asked Questions about the NHGRI budget.

Top of page

Research

Gene Discoveries for Common Complex Diseases 1990 – 2007
A slide illustrating the genes discovered, along with concurrent NIH initiatives, since the beginning of the Human Genome Project.
Cumulative Pace of Gene Discovery 1981 – 2005
A bar chart illustrating the number of disease genes identified from 1981 to 2005.
A Vision for the Future of Genomics Research
A scientific report that describes the future of the field of genomics.
Understanding Our Genetic Inheritance
The U.S. HGP, the First Five Years: Fiscal Years 1991-1995
A New Five-Year Plan for the United States Human Genome Project
Originally published in 1993 in Science.
New Goals for the U.S. Human Genome Project: 1998-2003
Originally published in 1998 in Science.
Ethical, Legal and Social Implications (ELSI) Research Program
The continuing research program established by NHGRI at the outset of the HGP that examines the ethical, legal and social implications of human genetic research.

Top of page

Model Organisms

Integral to the HGP are similar efforts to understand the genomes of various organisms commonly used in biomedical research, such as mice, fruit flies and roundworms. Such organisms are called "model organisms," because they serve as research models for how the human organism behaves.

Comparative Genomics
Background information prepared for the media on comparing the genomes of other species to the human sequence.
Background on Comparative Genomic Analysis
New Process to Prioritize Animal Genomes For Cloning and Sequencing
October 2001 News Release.
NHGRI Adds Cow and Dog To High Priority List For Sequencing Model Organisms
September 2002 News Release.
The Mouse Genome And The Measure of Man
December 2002 News Release.
Background on Mouse as a Model Organism
Background on the History of the Mouse
Progress Made in Sequencing Of Model Organisms’ Genomes
May 2003 News Release.
Report from the NIH/NIAID/Wellcome Trust Workshop on Model Organism Databases

To view the PDFs on this page you will need Adobe Reader.